Thyrocare Technologies Limited announced its quarterly financial results and key board decisions for the period ended December 31, 2025, following a board meeting held on January 28, 2026.

Financial Results Approval

The Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The financial statements were accompanied by limited review reports issued by the company's statutory auditors, MSKA & Associates LLP.

Standalone Financial Performance

Nine Months Performance

For the nine months ended December 31, 2025, the company reported revenue from operations of ₹563.60 crores compared to ₹459.23 crores in the corresponding period of the previous year, representing a growth of 22.7%. Net profit for the nine-month period stood at ₹105.23 crores versus ₹73.96 crores in the previous year.

Consolidated Results

The consolidated financial results showed revenue from operations of ₹195.53 crores for Q3 FY26 compared to ₹165.92 crores in Q3 FY25. Consolidated net profit reached ₹28.05 crores against ₹18.95 crores in the corresponding quarter of the previous year.

Exceptional Items Impact

The company reported exceptional items of ₹5.97 crores in Q3 FY26, primarily due to incremental gratuity impact of ₹4.01 crores arising from changes in wage definitions under the New Labour Codes implemented from November 21, 2025. Additional exceptional items of ₹1.96 crores were related to non-recurring costs associated with capital restructuring.

Code of Conduct Amendment

The Board approved amendments to the "Code of Conduct to Regulate, Monitor, and Report Trading by Designated Persons and their Immediate Relatives." This code ensures compliance with SEBI's Prohibition of Insider Trading Regulations, 2015. The amended code includes updated definitions, trading restrictions, and disclosure requirements for designated persons and their immediate relatives.

Bonus Share Details

The company had previously completed a 2:1 bonus share issuance approved by shareholders through postal ballot on November 16, 2025. The Stakeholders Relationship Committee allotted 10,61,07,794 equity shares of ₹10 each as fully paid-up bonus shares on December 1, 2025, to eligible members whose names appeared in the register as of November 28, 2025.

Business Segments

The company operates through three primary segments:

The diagnostic testing services segment, which forms the core business, showed strong growth of 20.1% year-over-year. The segment contributed ₹36.82 crores in profit before tax for Q3 FY26.

Corporate Governance

The board meeting commenced at 3:30 PM and concluded at 4:05 PM on January 28, 2026. All disclosures have been made available on the company's website and will be submitted to BSE and NSE as per regulatory requirements.

Thyrocare Technologies Limited announced the appointment of legendary actor Madhuri Dixit as its brand ambassador on January 27, 2026, coinciding with India's 77th Republic Day celebrations. The strategic partnership represents the diagnostic company's strengthened commitment to promoting preventive healthcare awareness across the country.

Strategic Partnership Details

The collaboration between Thyrocare and Madhuri Dixit focuses on three key areas:

Madhuri Dixit was selected beyond celebrity value for the trust and credibility she has earned over decades. Her discipline, consistency, and commitment to well-being mirror Thyrocare's philosophy that long-term health is built through small, regular actions, starting with knowing health parameters.

Leadership Statements

Rahul Guha, Managing Director & CEO, Thyrocare and API Holdings, commented on the appointment: "At Thyrocare, we exist to remove barriers such as price, access and inconvenience that keep people away from timely diagnostics. Preventive healthcare is the single biggest lever to improve health outcomes in India. Madhuri Dixit brings unmatched trust and credibility, and together, we want to make routine health check-ups a non-negotiable part of Indian life."

Madhuri Dixit expressed her enthusiasm about the partnership: "I strongly believe that taking charge of one's health early makes all the difference. Thyrocare has built its reputation on quality, affordability, and putting patients first. I'm proud to partner with a brand that is focused on empowering people to prioritise regular health check-ups."

Company Profile and Market Position

Thyrocare Technologies Limited operates as India's first fully automated laboratory chain with a strong presence across the country. The company has established itself as a leading diagnostics disruptor by delivering high-quality diagnostics at scale with affordable pricing.

Quality Accreditations

Thyrocare holds several internationally renowned quality certifications:

• ISO 9001-2000 rating obtained in 2001, upgraded to ISO 9001:2015
• National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation in 2005
• College of American Pathologists (CAP) accreditation in 2005

Strategic Vision

The appointment reinforces Thyrocare's long-term commitment to building a prevention-first healthcare ecosystem. The company aims to shift India's healthcare approach from reactive treatment to proactive health management, making informed decisions, early detection, and accessible diagnostics the foundation for better health outcomes for millions of Indians.

This partnership represents Thyrocare's continued efforts to expand access to quality diagnostic services while maintaining affordability, ensuring that routine health monitoring becomes an integral part of Indian households' healthcare practices.